<DOC>
	<DOCNO>NCT00095550</DOCNO>
	<brief_summary>The purpose clinical research learn moderate hypertension well control initially treat combination drug ( Irbesartan/HCTZ ) , patient unlikely achieve blood pressure ( B/P ) control one drug . In addition , study also evaluate safety tolerability drug .</brief_summary>
	<brief_title>Irbesartan/Hydrochlorothiazide ( HCTZ ) Combination Therapy Patients With Moderate Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Irbesartan</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>Willing provide write informed consent Subjects must uncontrolled hypertension define : average systolic blood pressure 160 mmHg 180 mmHg ( diastolic blood pressure le 110 mmHg ) average diastolic blood pressure 100 mmHg 110 mmHg ( systolic blood pressure 130 mmHg 180 mmHg ) Subjects must willing discontinue antihypertensive medication , applicable . Men woman , age 18 older include . Women childbearing potential ( WOCBP ) must use adequate method contraception avoid pregnancy throughout study one week study manner risk pregnancy minimize . WOCBP must negative serum urine pregnancy test within 72 hour prior start study medication . Women pregnant breastfeed Known suspect secondary hypertension Hypertension emergencies stroke within past 12 month . Heart attack , angina bypass surgery within past six month . Significant kidney disease Significant liver disease Systemic lupus erythematosus Gastrointestinal disease surgery interfere drug absorption Cancer past five year exclude localize squamous cell basal cell carcinoma skin Currently pregnant lactate Mental condition ( psychiatric organic cerebral disease ) render subject unable understand nature , scope , possible consequence study Drug alcohol abuse within last five year Known allergy irbesartan diuretic</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>Moderate Hypertension</keyword>
</DOC>